Mediphage Bioceuticals

About:

Developing safe and effective gene delivery platforms to unlock the therapeutic power of personalized, redoseable genetic medicine.

Website: https://www.mediphage.ca/

Twitter/X: mediphage

Top Investors: Creative Destruction Lab (CDL), Wing Venture Capital, Viking Global Investors

Description:

Mediphage Bioceuticals is a genetic medicine company focused on developing safe, effective, and personalized transgene delivery platforms for the delivery of genes into cells for gene therapy, cell engineering and gene editing. Our flagship technology, ministring DNA (msDNA) is the safest transgene delivery vector on the market that does not compromise effectiveness and can be produced at a fraction of the cost of competing solutions.

Total Funding Amount:

$4.15M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Toronto, Ontario, Canada

Founded Date:

2016-01-15

Founders:

Roderick Slavcev

Number of Employees:

11-50

Last Funding Date:

2019-03-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai